Atea Pharmaceuticals (AVIR) Depreciation & Amortization (CF) (2019 - 2026)

Atea Pharmaceuticals' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $104000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $104000.0; the TTM figure through Mar 2026 stood at $416000.0 (changed 0.0% YoY), while the FY2025 annual figure was $416000.0, changed 0.0% from the prior year.
• Depreciation & Amortization (CF) was $104000.0 for Q1 2026 at Atea Pharmaceuticals, roughly flat from $104000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $106000.0 in Q3 2022 to a low of $7000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $94823.5 across 5 years, with a median of $104000.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) jumped 1414.29% in 2022, then dropped 1.89% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $104000.0 in 2022, then changed by 0.0% to $104000.0 in 2023, then changed by 0.0% to $104000.0 in 2024, then changed by 0.0% to $104000.0 in 2025, then changed by 0.0% to $104000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $104000.0 (Q1 2026), $104000.0 (Q4 2025), and $104000.0 (Q3 2025), per Business Quant data.